Eli Lilly (LLY) Among Most Profitable Blue Chip Stocks for Hedge Funds

According to a report by Insider Monkey, Eli Lilly and Company (NYSE:LLY) ranks among the most profitable blue chip stocks favored by hedge funds. With a profit margin of 34.99% and net income of $20.64 billion for fiscal year 2025, LLY stands out as an attractive investment.

Recommendation Change

The report does not specify a particular analyst rating change but indicates that analysts see 9.20% upside from current levels.

Analyst Rationale

The rationale behind the stock's appeal lies in its high profit margins (34.99%) and strong net income ($20.64 billion), making it one of the most profitable blue chip stocks. Ongoing regulatory and clinical activities also support positive expectations.

Context

This positive outlook comes during a period of active regulatory and clinical news for Lilly. The report does not detail other analyst opinions or recent stock performance.

Conclusion

The data suggests that Eli Lilly maintains a strong position among blue chip stocks in terms of profitability, attracting hedge fund interest. Investors should monitor future regulatory and clinical developments that could impact the stock.